(Q36788459)

16 August 2017

1 reference

title

Bevacizumab in the management of solid tumors (English)

1 reference

16 August 2017

1 reference

Roy L Pañares

1

1 reference

16 August 2017

Agustin A Garcia

series ordinal

2

1 reference

16 August 2017

publication date

1 April 2007

1 reference

Expert Review of Anticancer Therapy

16 August 2017

published in

1 reference

16 August 2017

volume

7

1 reference

16 August 2017

issue

4

1 reference

16 August 2017

page(s)

433-445

1 reference

Changes in the vascular extracellular matrix during embryonic vasculogenesis and angiogenesis.

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

VEGF and imaging of vessels in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

Vascular endothelial growth factors and angiogenesis in eye disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

What Is the Evidence That Tumors Are Angiogenesis Dependent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

The biology of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

Regulators of Angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

Vascular endothelial growth factor is a secreted angiogenic mitogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

Regulation of vascular endothelial growth factor expression in human colon cancer by interleukin-1beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

Vascular endothelial growth factor: basic science and clinical progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

Specificity, diversity, and convergence in VEGF and TNF-alpha signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

Maximizing the potential of bevacizumab in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

Managing patients treated with bevacizumab combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

Reversible posterior leukoencephalopathy syndrome and bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

Nasal Septum Perforation in a Bevacizumab-Treated Patient with Metastatic Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.433

21 January 2018

Identifiers

DOI

10.1586/14737140.7.4.433

1 reference

release_fz4foiwsinbxhm7ms5urc7nyoa

16 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fz4foiwsinbxhm7ms5urc7nyoa

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference